IMMX
HealthcareImmix Biopharma, Inc. · Biotechnology · $480M
What is Immix Biopharma, Inc.?
Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing tissue-specific therapeutics targeting oncology and inflammatory diseases. Headquartered in Los Angeles, California, the company operates across the United States and Australia.
Immix Biopharma generates no commercial revenue at this stage — its pipeline candidates are progressing through clinical trials. The company's approach centers on tissue-specific drug delivery designed to concentrate therapeutic effect at the disease site. Its lead program, IMX-110, is in Phase 1b/2a trials for soft tissue sarcoma and solid tumors, including a collaboration with BeiGene Ltd. combining IMX-110 with an anti-PD-1 therapy. Additional candidates target colorectal cancer and inflammatory bowel diseases.
Immix Biopharma was incorporated in 2021 and is based in Los Angeles, California.
- IMX-110 — oncology candidate in Phase 1b/2a for soft tissue sarcoma and solid tumors
- IMX-111 — tissue-specific biologic targeting colorectal cancers
- IMX-120 — biologic candidate for ulcerative colitis and severe Crohn's disease
- Clinical collaboration with BeiGene Ltd. for combination solid tumor trial
Is IMMX a Good Stock to Buy?
UQS Score rates IMMX as Poor overall, reflecting the early-stage nature and significant uncertainties typical of pre-revenue clinical biotechs.
Among the five pillars, Risk is the least concerning — the company carries a Neutral Risk rating, which may reflect a manageable near-term liability structure relative to its development stage. This is a modest relative positive within an otherwise challenging profile.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products, no commercial revenue, and an unproven competitive position. Valuation is rated Elevated, suggesting the market may already be pricing in optimistic clinical outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does IMMX pay dividends?
No — Immix Biopharma, Inc. does not currently pay a dividend.
Immix Biopharma does not pay a dividend, which is standard for clinical-stage biotechs. All available capital is directed toward funding clinical trials and advancing the pipeline. Investors in companies like IMMX are typically seeking potential long-term appreciation from successful drug development rather than current income.
When does IMMX report earnings?
Immix Biopharma reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial updates tend to be the most market-relevant disclosures.
For the most current quarterly results and clinical updates, visit Immix Biopharma's investor relations page directly.
IMMX Price History
+171.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Immix Biopharma, Inc.?
Based on Immix Biopharma, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
IMMX Long-term Outlook
With Growth and Quality both rated Weak, the near-term fundamental outlook for IMMX is heavily dependent on clinical trial outcomes rather than organic business momentum. The Elevated Valuation rating suggests limited margin of safety if trial results disappoint. The Neutral Risk rating provides a modest buffer, but the path to value creation runs almost entirely through pipeline execution and potential partnership or licensing activity.
Growth drivers
- Positive Phase 1b/2a data readouts for IMX-110 in solid tumors
- Expansion of the BeiGene collaboration or new partnership agreements
- Advancement of IMX-111 or IMX-120 into later-stage trials
Key risks
- Clinical trial failure or safety signals in any pipeline candidate
- Elevated valuation leaves little room for setbacks or delays
- Ongoing cash burn without commercial revenue increases dilution risk
IMMX vs Peers
Immix Biopharma operates in a crowded clinical-stage space alongside other pre-revenue or early-revenue biotechs pursuing differentiated therapeutic approaches.
Relmada focuses on central nervous system disorders, pursuing a distinct therapeutic area from Immix's oncology and inflammation pipeline.
Absci applies AI-driven protein design to drug discovery, representing a technology-platform model rather than a traditional clinical development approach.
Tectonic Therapeutic targets GPCR biology with a focus on cardiovascular and metabolic diseases, differentiating it from Immix's tissue-specific oncology strategy.
Frequently Asked Questions
What does Immix Biopharma do?
Immix Biopharma is a clinical-stage company developing tissue-specific therapeutics for oncology and inflammatory diseases. Its pipeline includes candidates for soft tissue sarcoma, colorectal cancer, ulcerative colitis, and Crohn's disease. The company has no approved products and generates no commercial revenue at this time.
Does IMMX pay dividends?
No, Immix Biopharma does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and clinical development. Investors in IMMX are generally seeking potential long-term value from pipeline success rather than income.
When does IMMX report earnings?
Immix Biopharma follows a standard quarterly reporting cadence for US-listed companies. For exact dates and the most recent financial disclosures, check the company's investor relations page directly.
Is IMMX a good stock to buy?
UQS Score rates IMMX as Poor, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. This profile reflects the high uncertainty inherent in pre-revenue clinical biotechs. Investors should weigh pipeline risk carefully. The full pillar breakdown is available to UQS Pro members.
Is IMMX overvalued?
The UQS Valuation pillar for IMMX is rated Elevated, suggesting the current market price may reflect optimistic assumptions about clinical outcomes. For a company with no commercial revenue and multiple early-stage candidates, an elevated valuation leaves limited room for trial setbacks.
How does IMMX compare to its competitors?
Compared to peers like Relmada Therapeutics, Absci Corporation, and Tectonic Therapeutic, Immix occupies a distinct niche with its tissue-specific oncology and inflammation focus. Each peer pursues different therapeutic areas or technology platforms. UQS Pro members can view side-by-side quality scores for direct comparison.
What is IMMX's market cap bracket?
Immix Biopharma is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility and liquidity risk compared to mid- or large-cap peers, which is common among clinical-stage biotechs.
Who founded Immix Biopharma?
Immix Biopharma was incorporated in 2021 and is headquartered in Los Angeles, California. For detailed founding history and leadership background, the company's official website and SEC filings are the most reliable sources.
Is IMMX a long-term quality investment?
As a long-term quality indicator, UQS rates IMMX as Poor. The Weak scores across Quality, Moat, and Growth pillars reflect the absence of durable competitive advantages and commercial revenue at this stage. Long-term value depends almost entirely on clinical trial success and eventual commercialization.
What is the main competitive advantage of Immix Biopharma?
Immix's stated differentiation is its tissue-specific therapeutic approach, designed to concentrate drug activity at the target site. However, the UQS Moat pillar rates this as Weak, reflecting that the competitive advantage has not yet been validated through commercial success or proven clinical superiority.
What sector does IMMX belong to?
Immix Biopharma operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. This sector is characterized by binary clinical risk, long development timelines, and significant capital requirements before any commercial revenue is generated.
Is IMMX a growth stock or value stock?
Based on UQS pillar labels, IMMX does not fit neatly into either category. The Growth pillar is rated Weak, reflecting no revenue trajectory, while the Valuation pillar is Elevated — meaning it is neither a traditional value opportunity nor a fundamentally supported growth story at current levels.
Unlock Full IMMX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare IMMX against sector peers by quality score
- ✓Screen for higher-rated biotech alternatives
- ✓Get the full risk and valuation deep-dive
Pro Analysis
IMMX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 7.7 | 0.0 | 3.0 | 0.0 | 46.2 | 0.0 | -1.3 |
| May 8, 2026 | 9.0 | 0.0 | 3.0 | 0.4 | 54.7 | 0.0 | +1.1 |
| Apr 2, 2026 | 7.9 | 0.0 | 3.0 | 0.5 | 47.1 | 0.0 | — |
IMMX — Pillar Breakdown
Quality
— 0.0/100 (25%)Immix Biopharma, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.4/100 (20%)Immix Biopharma, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 54.6/100 (15%)Immix Biopharma, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Immix Biopharma, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 3/100 (25%)Immix Biopharma, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IMMX.
Score Composition
Financial Data
More Stock Analysis
How is the IMMX UQS Score Calculated?
The UQS (Unified Quality Score) for Immix Biopharma, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Immix Biopharma, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Immix Biopharma, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.